Support program for newly diagnosed rectal cancer patients
Part of Cancer, Digestive system clinical trials.
This trial tests an informational and supportive care program for people with newly diagnosed, locally advanced rectal cancer. It may help by providing education and practical support around next steps in treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You are within 8 weeks of deciding on a plan that includes multiple types of treatment for newly diagnosed rectal cancer (stage II or III)
- You can complete study visits and forms in English, or you can use an interpreter
- Your cancer care team does not think another health problem will get in the way of taking part
- You have not had treatment for a prior colorectal (colon or rectal) cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach for people with locally advanced rectal cancer that has high-risk features. It combines short-course radiation with chemotherapy (CapeOX) and the immunotherapy drug toripalimab, with or without another drug called surufatinib, before surgery. The goal is to see if adding these drugs helps shrink the tumor and improve outcomes.
This trial studies how to improve bowel symptoms in people treated for rectal cancer. It tests personalized care plans and looks at different factors that may contribute to bowel problems after surgery or a watch-and-wait approach.
This study tests whether a more intensive follow-up program after rectal cancer surgery can improve your recovery, daily function, and overall quality of life. If you've had a temporary ileostomy and are waiting for reversal, this extra support may help you feel better faster.
This trial tests a program that helps you and your doctor decide together whether to avoid surgery and keep your rectum after chemo and radiation. It's for people with early-stage rectal cancer who have not had prior treatment for this cancer.
This study compares two treatment approaches for patients with locally advanced rectal cancer. One group gets a short course of radiation followed by chemotherapy combined with an immunotherapy drug called a PD-1 inhibitor, while the other group gets radiation and chemotherapy alone. The trial aims to see if the PD-1 inhibitor improves outcomes and whether a natural substance in the blood called beta-hydroxybutyrate can predict response.
This study uses online surveys through your patient portal to track your symptoms and quality of life during rectal cancer care. It aims to make it easier for you to share how you're feeling with your care team.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.